Slide 1: Stock exchange filing cover letter for press release
May 18, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Madam/ Sir, Sub: Press Release Ref: Regulation
Slide 2: Strides Delivers Strong Performance with FY26 EBITDA Growth
Press Release 18th May 2026 Strides Delivers Strong Performance with FY26 EBITDA 53m, 81m, 50% YoY Growth Ex US Markets Outperform with 21% YoY Revenue Growth; Disciplined Execution Expands EBITDA Margin to 19% Strides Board Recommends a 5 per share FY2026 Performance Highlights US Market Revenue at
Slide 3: About Strides
Press Release 18th May 2026 About Strides Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly rategy and an institutional business to service donor- located in India
Slide 4: Stock exchange filing cover letter for investor presentation
May 18, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai – 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Sirs, Sub: Earnings Presentation for the qua
Slide 5: Strides Pharma Science Limited
May 18, 2026 Strides Pharma Science Limited Health where it matters
Slide 6: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 7: Operational PAT and Operational EPS Grew 50% YoY
Operational PAT and Operational EPS Grew 50% YoY FY26 FY25 YoY Change Strides continued to deliver strong performance across profitability, efficiency, and growth metrics 48,587 45,653 YoY 6.4% during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY. Our conti
Slide 8: Q4FY26 Performance Highlights
Q4FY26 Q4FY25 YoY Change 13,235 11,904 YoY 11.2% US Market Ex-US Markets Access Markets 7,872 6,914 13.9% Gross Margin (%) 59.5% 58.1% 140bps 2,397 2,179 10.0% EBITDA Margin (%) 18.1% 18.3% -20bps 1,357 1,130 20.0% 14.7 12.3 20.0% 1,293 856 51.0% Q4FY25 Q4FY26 Operational PAT = Reported PAT excludin
Slide 9: Sustained Growth Across P&L Metrics Over the Last 3 Years
Sustained Growth Across P&L Metrics Over the Last 3 Years Profitability Focus Delivers Superior PAT Performance, Outperforming Revenue and EBITDA growth Gross Margin Gross Margin (%) EBITDA EBITDA (%) CAGR 12% CAGR 330% CAGR 16% CAGR 26% 35, 000 70. 0% 10,000 19.0% 20.0% 17.6% 59.7% 9,000 18.0% 30,
Slide 10: Ex-US Market Registers a Strong Growth Over FY24-26
Ex-US Market Registers a Strong Growth Over FY24-26 Growth Across Regions in Ex-US Markets Offsets Decline in Access Market Ex- US ORM ORM Growth Market Growth Market Access Market 3% CAGR 11% CAGR 19% CAGR -34% 8% 6% 12% 10% 11% 30% 31% 34% 52% 54% 51% FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 F
Slide 11: US Market
8 Strides US Market Health where it matters
Slide 12: FY26 US Revenue at $284m, Steady Despite New Entrants and Weak Flu Season
FY26 Revenue at $284m, Remained Steady Despite New Entrants in Recent Launches and Weak Flu Season in H2 Year-on-Year Comparison Comments FY26 revenue at $284m, reflects H2 seasonality headwinds YoY 2% Launched 6 products in FY26 $291 $284 Discontinued 9 products in FY26 that did not meet our margin
Slide 13: Ex-US Market
8 Strides Ex-US Market Health where it matters
Slide 14: Ex-US Market Revenue at $254m, Grew 21% YoY
Ex-US Market Revenue at $254m, Grew 21% YoY Driven by Strong Performance Across Markets Year-on-Year Comparison Comments Other Regulated Markets YoY 21% $254 All regulated markets except US form part of the Other Regulated Markets $221 Focus on ORM playing out in FY26 with revenue at $186m, Grew 21%
Slide 15: Strong Financial Discipline Enabled Profitable Growth
Strong Financial Discipline Enabled Profitable Growth Health where it matters
Slide 16: Income Statement
Income Statement Particulars Q4FY26 Q4FY25 YoY Q3FY26 QoQ FY26 FY25 YoY I. Revenue 13,235 11,904 11.2% 11,946 10.8% 48,587 45,653 6.4% II. Material Costs 5,362 4,989 4,629 19,587 19,799 III. Gross Margin (I- II) 7,872 6,914 13.9% 7,317 7.6% 29,000 25,854 12.2% Gross Margin % 59.5% 58.1% 140 bps 61.2
Slide 17: Net Debt and Net Finance Cost
Fx FY25 FY26 Working Capital Loans 11,364 9,476 Long Term Loans 6,593 5,907 Interest Cost on Borrowings (A) 1,983 1,406 Gross Debt 17,956 15,383 Other Finance Charges (B) 505 379 Cash and Cash Equivalents (2,734) (2,133) Net Debt at Constant Currency 15,222 13,250 Finance Income (C) 532 405^ Currenc
Slide 18: Continued Steady Performance Across Key Metrics Despite External Headwinds
Continued Steady Performance Across Key Metrics, Despite Adverse Impact of External Headwinds Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 0.98 3.47 129 124 117 0.59 1.90 0.46 1.55 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Current Ratio (x) RoCE (%) Fixed Asset Turnover
Slide 19: Balance Sheet
Balance Sheet Strong Corporate Governance and Corporate Actions improved the Balance Sheet position Particulars (In ) 31-Mar-24 31-Mar-25 31-Mar-26 Assets Net Tangible Assets ( including CWIP) 8,809 9,220 10,756 Right-of-use assets 895 695 782 Goodwill and Other Intangibles 10,565 11,145 13,941 Inve
Slide 20: Corporate Updates
8S Strides Corporate Updates Health where it matters
Slide 21: Strengthening Executive Management on the Board
Strengthening Executive Management on the Board Leadership to Support Long-term Growth Strategy New Board Member - Executive Director Ramaraju PVS Expertise: Pharmaceutical Chemistry and has vast experience in the pharmaceutical and healthcare sectors He has been part of Strides group for over 18 ye
Slide 22: Q4FY26 Earnings Call Details
Q4FY26 Earnings Call Details invites you to interact with the senior management on Q4FY26 Performance Click Here pre-register and join without the operator May 18, 2026 5:00 pm IST / 11:30 am GMT / 7:30 am EDT / 7:30 pm HKT ` Participants from the Management would be: Badree Komandur Vikesh Kumar Jo
Slide 23: To know more: www.strides.com
Health where it matters Youtube logo Images - Free Download on Freepik To know more: www.strides.com Investor-relations@strides.com Stay Connected © 2026 Strides Pharma All Rights Reserved. This presentation is intended solely for the use of the individual or entity to whom it is addressed. If you a